Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1021/acs.orglett.0c03052 http://scihub22266oqcxt.onion/10.1021/acs.orglett.0c03052 33085486!7653677!33085486     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Org+Lett 2020 ; 22 (21): 8430-8435 Nephropedia Template TP {{tp|p=33085486|t=2020. Cyanoamidine Cyclization Approach to Remdesivir s Nucleobase |pdf=|usr=}}{{33085486}} gab.com Text Cyanoamidine Cyclization Approach to Remdesivir s Nucleobase JO: Org Lett http://www.kidney.de/pget.php?&tw=1&pmid=33085486 #FOAvip We report an alternative approach to the unnatural nucleobase fragment seen in remdesivir (Veklury). Remdesivir displays broad-spectrum antiviral activity and is currently being evaluated in Phase III clinical trials to treat patients with COVID-19. Our route relies on the formation of a cyanoamidine intermediate, which undergoes Lewis acid-mediated cyclization to yield the desired nucleobase. The approach is strategically distinct from prior routes and could further enable the synthesis of remdesivir and other small-molecule therapeutics. Twit Text FOAVip Cyanoamidine Cyclization Approach to Remdesivir s Nucleobase ????Org Lett http://www.kidney.de/pget.php?&tw=1&pmid=33085486 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33085486 #FOAvip English Wikipedia <ref>{{Cite pmid|33085486}}</ref> Cyanoamidine Cyclization Approach to Remdesivir s Nucleobase #MMPMID33085486 Knapp RR; Tona V; Okada T; Sarpong R; Garg NK Org Lett 2020[Nov]; 22 (21): 8430-8435 PMID33085486show ga We report an alternative approach to the unnatural nucleobase fragment seen in remdesivir (Veklury). Remdesivir displays broad-spectrum antiviral activity and is currently being evaluated in Phase III clinical trials to treat patients with COVID-19. Our route relies on the formation of a cyanoamidine intermediate, which undergoes Lewis acid-mediated cyclization to yield the desired nucleobase. The approach is strategically distinct from prior routes and could further enable the synthesis of remdesivir and other small-molecule therapeutics. |Adenosine Monophosphate/*analogs & derivatives/chemical synthesis/chemistry/therapeutic use[MESH] |Alanine/*analogs & derivatives/chemical synthesis/chemistry/therapeutic use[MESH] |Amidines/*chemistry[MESH] |Antiviral Agents/*chemical synthesis/*chemistry/therapeutic use[MESH] |COVID-19[MESH] |Chemistry Techniques, Synthetic[MESH] |Coronavirus Infections/drug therapy[MESH] |Cyclization[MESH] |Pandemics[MESH]Cyanoamidine Cyclization Approach to Remdesivir s Nucleobase (epmc).pdf DeepDyve Pubget Overpricing